Genistein, an isoflavone abundantly present in soybeans, has structural similarity to estrogen, suggesting that genistein may act as a phytoestrogen. To examine the possible role of genistein in hemopoiesis and bone metabolism, female mice were either sham-operated or ovariectomized (OVX), and selected OVX mice were administered genistein for 2-4 weeks (0.1-0.7 mg/day) or 17␤-estradiol (E 2 ; 0.01-0.1 g/day) sc, using a miniosmotic pump (Alza Corp., Palo Alto, CA). In OVX mice, uterine weight declined but was completely restored by E 2 administration. In contrast, genistein did not demonstrate a reversal of the OVX-induced uterine atrophy. The number of bone marrow cells markedly increased, 2-4 weeks after OVX, and most of these were B220-weakly positive pre-B cells. The increased B-lymphopoiesis was completely restored, not only by E 2 but also by genistein administration. In OVX mice, the trabecular bone volume of the femoral distal metaphysis, measured by microcomputed tomography scanning and dual-energy x-ray absorptiometry, was markedly reduced; and genistein restored this, as did E 2 . These results indicate that genistein exhibits estrogenic action in bone and bone marrow, to regulate B-lymphopoiesis and prevent bone loss, without exhibiting estrogenic action in the uterus. Phytoestrogens may be useful for preventing bone loss caused by estrogen deficiency in females. (Endocrinology 140: [1893][1894][1895][1896][1897][1898][1899][1900] 1999) 
B ONE MASS IS influenced by a number of factors, such
as genetics, nutrition, hormonal conditions, exercise, and life style. It is well known that estrogen deficiency induces rapid bone loss during the first decade after menopause. Estrogen replacement therapy is indeed effective in preventing bone loss caused by menopause, but it is accompanied by some adverse effects, such as uterine bleeding and carcinogenesis (1) . Therefore, recent studies have focused on the development of estrogen-related compounds that selectively affect bone metabolism without exhibiting estrogenic action in the uterus. Some of the synthetic estrogen-related compounds, such as raloxifene, preferentially act as an agonist on bone and cardiovascular systems and prevent postmenopausal symptoms caused by estrogen deficiency, whereas they antagonize the effects of estrogen in reproductive tissues (2) . These compounds are known as selective estrogen receptor modulators and are currently available for the prevention of osteoporosis.
Epidemiological studies suggest that the low incidence of osteoporosis and heart diseases caused by estrogen deficiency in Asian women is attributable to their high intake of soyfoods, compared with American and Finnish women (3) (4) (5) . It is reported that dietary soybean proteins prevent bone loss in ovariectomized (OVX) rats (6) . Possible candidates for the beneficial substances present in soybeans are isoflavones, such as genistein and daidzein, because these isoflavones show a structural similarity to estradiol (E 2 ) and are known as phytoestrogens. Although these isoflavones have been reported to bind to estrogen receptors and protect cell growth in breast cancer cells (7) (8) (9) (10) , it is less known whether these isoflavones affect bone metabolism. Furthermore, it has been reported that genistein acts as an inhibitor of tyrosine kinase (11) .
We have reported that an estrogen deficiency caused by OVX selectively stimulates B-lymphopoiesis, resulting in an accumulation of pre-B cells in mouse bone marrow (12) . Both increased B-lymphopoiesis and bone loss in OVX mice were restored by treatment with estrogen (12) . It was assumed that the increased B-lymphopoiesis caused by estrogen deficiency was involved in stimulating bone resorption. This is because the increased B-lymphopoiesis, induced by the administration of interleukin (IL)-7, resulted in marked bone loss caused by stimulated osteoclastic bone resorption in mice with intact ovarian function (13) . Recent studies suggest that boneresorbing cytokines, such as IL-1, IL-6, and tumor necrosis factor ␣, may be involved in bone loss caused by estrogen deficiency (14 -18) . We found that pre-B cells proliferate on bone marrow stromal cells and make them produce boneresorbing cytokines, such as IL-6. Therefore, B-lymphopoiesis in bone marrow seems to be closely related to bone metabolism, which is regulated by estrogen. Thus, it is important to clarify whether soybean isoflavones have estrogenic action in bone and bone marrow.
In this study, we examined the effects of genistein, a typical soybean isoflavone, on B-lymphopoiesis and bone mass in OVX mice to see whether genistein shows an estrogenic property in bone and bone marrow. Genistein did, in fact, exhibit estrogenic properties in bone and bone marrow without exhibiting estrogenic action in the uterus.
Materials and Methods

Animals and drugs
Eight-week-old female mice of the ddy strain were obtained from Shizuoka Laboratory Animal Center (Shizuoka, Japan). Mice were either sham-operated or OVX. Some OVX mice were sc administered with either genistein (Extrasynthese, Genay, France) or E 2 (Sigma Chemical Co., St. Louis, MO), dissolved in 20% dimethylsulfoxide in polyethylenglycol-300 using a mini-osmotic pump (Alza Corp., Palo Alto, CA), immediately after surgery. Genistein is a typical soybean isoflavone, and it shows a structural similarity to E 2 ( Fig. 1) . Control mice were treated with a vehicle solution. The mice were fed a normal diet, containing 1.12% calcium and 1.07% phosphorus (Nippon Clea, Tokyo, Japan), for 2-4 weeks after the surgery, under specific pathogen-free conditions. In another series of experiments, 8-week-old female ddy mice were administered with genistein or E 2 sc, using a mini-osmotic pump, for 2 weeks under the same conditions. In each experiment, the uterine weight was measured, and the right and left tibiae were removed to prepare bone marrow cells. For the measurement of bone mineral density (BMD), femora were dissected 4 weeks after surgery. All procedures were in accordance with The National Institute of Health and Nutrition Guidelines for the Care and Use of Laboratory Animals.
Flow cytometric analysis
Immunofluorescence analysis of the bone marrow cells was performed according to the method previously described (12) . In short, bone marrow cells were prepared from the right and left tibiae by flushing out the bone marrow with Ca 2ϩ -and Mg 2ϩ -free PBS [PBS(Ϫ)] using a syringe with a 27-gauge needle. The cells were centrifuged and resuspended in 2 ml ammonium chloride-Tris buffer to lyse red blood cells. The cell suspension was washed in PBS(Ϫ) three times and resuspended in 1 ml PBS (Ϫ) containing 1% BSA. The bone marrow cells (1 ϫ 10 6 ) were incubated for 30 min on ice with fluorescein isothiocyanate (FITC)-conjugated antibodies for B220 (RA3-6B2; PharMingen, San Diego, CA) or Gr-1(RB6Ϫ8C5; PharMingen), which are specific markers for B lymphocytes and granulocytes, respectively. These cells were washed twice and resuspended in PBS(Ϫ) containing 1% BSA. As a negative control, FITC-conjugated rat IgG was used. Stained cells were analyzed with a flow cytometry (FACScan, Becton Dickinson and Co., San Jose, CA).
Radiographic analysis of the femur
Radiographic analysis of the femora was performed using a soft x-ray system. The BMD of the femur was measured by dual x-ray absorptiometry (model DCS-600R; Aloka, Tokyo, Japan). The bone mineral content of the mouse femur was closely correlated with the ash weight (r ϭ 0.978) (13) . BMD was calculated by bone mineral content of the measured area. The scanned area of mouse femur was equally divided into three parts (5.3 mm each): proximal femur, mid shaft, and distal femur.
Three-dimensional analysis of trabecular microarchitecture by microcomputed tomography (CT)
The femoral cancellous bone of the distal metaphysis was analyzed three-dimensionally by the CT system (CT-20; Scanco Medical, Zurich, Switzerland), as reported by Ruegsegger et al. (19) . The mean tissue volume (TV) of the scanned area was 0.44 mm 3 in the trabecular bone of the femoral distal metaphysis, which did not include any cortical bone. Using 200 two-dimensional computed tomography images of 8-m thickness, a three-dimensional microstructural image was reconstructed to calculate morphometric indices, such as bone volume (BV) fraction (BV/TV), trabecular thickness [Tb.Th ϭ 2 ϫ BV/bone surface (BS)], and trabecular separation [Tb.Sp ϭ (1/Tb.N) Ϫ Tb.Th], where Tb.N is trabecular number. These parameters were calculated using the parallel plate model developed by Parfitt et al. (20) . The Tb. N was defined as the number of intersections between bone and nonbone components per total length of test lines applied to a specimen (21) .
Histomorphometry
Undecalcified 5-m sections were prepared from femora and were stained for tartrate-resistant acid phosphatase (TRAP). Histomorphometry was performed with the semiautomatic image analyzing system (System Supply, Nagano, Japan) linked to a light microscope. Using the sections of distal femora, histomorphometric parameters were quantified in cancellous bone tissue at secondary spongiosa. The region in the trabecular bone within one cortical width from the endosteal surface was excluded from the measurements. 
Statistical analysis
Data were expressed as means Ϯ sem. The significance of the differences was determined by ANOVA and Fisher's protected least-significant-difference test (Stat view 4.0, Abacus Concepts, Calabasas, CA). Differences were considered significant at the level of P Ͻ 0.05. Figure 2 shows the time course of change in body weight, uterine weight, and the number of nucleated cells in the bone marrow after OVX. It also shows the effects of the treatment with genistein (0.5 mg/day) and E 2 (0.01 g/day) on those parameters in OVX mice. Four weeks after surgery, OVX mice exhibited a significant increase in body weight, compared with sham-operated mice; and treatment with genistein or E 2 restored them to the sham level ( Fig. 2A) . Uterine weight strikingly decreased in OVX mice, 2 weeks after surgery, indicating that the mice were estrogen deficient ( weight at all in OVX mice. A histological study indicated that the atrophy of uterine epithelial cells in OVX mice was not restored by the treatment with genistein (data not shown). As reported previously (12) , OVX caused a significant increase in the number of nucleated cells in bone marrow, and the increased hemopoiesis was corrected with estrogen treatment, to the sham level (Fig. 2C ). Genistein also restored the OVX-induced stimulation of bone marrow hemopoiesis to the same level as that of sham mice (Fig. 2C) . These results indicate that genistein regulates bone marrow hemopoiesis without exhibiting estrogenic action in the uterus, at least at this dose level.
Results
Effects of genistein on bone marrow hemopoiesis and uterine atrophy in OVX mice
We previously reported that the stimulated bone marrow hemopoiesis in OVX mice consists of B220-positive pre-B cells and that the estrogen treatment restores the increased level of B-lymphopoiesis in OVX mice to the sham level (12) . To evaluate the effects of genistein on bone marrow hemopoiesis in OVX mice, the population of bone marrow cells was analyzed by flow cytometry. Figure 3 shows the expression pattern of B220-positive B cells in sham-operated mice, OVX mice, and OVX mice treated with genistein or E 2 . As reported previously (12) , the percentage of B220-positive B cells was markedly enhanced in OVX mice, 2 weeks after surgery (Fig. 3) . When OVX mice were treated with 0.5 mg/ day of genistein, the level of B220-positive cells returned to the sham level, and its effect was similar to that of 0.1 g/day E 2 (Fig. 3) . Table 1 shows the dose response effect of genistein on the percentages of B220-positive B cells and Gr-1-positive granulocytes of bone marrow cells in OVX mice. In contrast to the increase in B220-positive cells, the percentage of Gr-1-positive cells decreased in OVX mice, as reported previously (12, Table 1 ). Because the total number of bone marrow cells increased, the absolute number of granulocytes was unchanged in OVX mice (12) . When OVX mice were treated with genistein, at 0.5-0.7 mg/day, the percentages of B220-positive cells and Gr-1-positive cells returned to the sham levels ( Table 1 ). The effects of genistein on bone marrow hemopoiesis were similar to those of E 2 . Estrogen replacement completely restored uterine atrophy in OVX mice, but genistein (at 0.1-0.7 mg/day) did not affect the uterine weight at all.
Effects of genistein on bone marrow B-lymphopoiesis in normal mice
To evaluate the effects of genistein on bone marrow hemopoiesis and on uterine weight, normal female mice were treated with 0.5 mg/day genistein. Neither uterine weight nor the percentage of B220-positive cells in the bone marrow were affected by genistein treatment over 2 weeks in normal mice (Table 2 ). In contrast, treatment with estrogen resulted in a significant increase in the uterine weight and a decrease in the percentage of B cells in normal female mice. When normal mice were administered with genistein (0.7 mg/day) and E 2 (0.1 g/day) concurrently, genistein did not alter the uterotrophic and suppressive effects on B-lymphopoiesis induced by E 2 (data not shown). These results indicate that genistein, at 0.1-0.7 mg/day, does not exhibit estrogenic action in uterine wet weight in mice with intact ovarian function.
Effect of genistein on bone mass in OVX mice
To examine the effects of genistein on bone mass, OVX mice were treated for 4 weeks with 0.7 mg/day of genistein, and femora were used for radiographic analysis. The x-ray analysis revealed that the mineralized cancellous bone mass significantly decreased, especially in the distal metaphysis of the femur, in OVX mice (Fig. 4) . Treatment with genistein (at 0.7 mg/day) or E 2 (at 0.01 g/day) markedly prevented the bone loss from the distal metaphysis in OVX mice (Fig. 4) . Effects of genistein on bone mass in OVX mice were further determined by measuring BMD at proximal, middle, and distal regions of the femur, 4 weeks after surgery. The BMD was significantly reduced by OVX, especially at the distal metaphysis, and the decreased BMD was significantly restored by the administration of 0.7 mg/day genistein (Table 3) . Estrogen, Body weight and uterine weight were measured 2 weeks after the operation. Bone marrow cells were collected from sham mice, OVX mice and OVX mice treated with genistein or E 2 2 weeks after surgery, and the total number of nucleated cells was counted. The expression of B220 and Gr-1 was analyzed by flow cytometry after staining the bone marrow cells with monoclonal antibody. The percentage of positive cells was then calculated. Data are expressed as the means Ϯ SEM of 4 -8 mice.
a Significantly different from the sham mice: P Ͻ 0.01. Body weight and uterine weight were measured 2 weeks after administration of vehicle, genistein or E 2 . Bone marrow cells were collected from the mice in each group 2 weeks after the treatment, and the total number of nucleated cells was counted. The expression of B220 was analyzed by flow cytometry after staining bone marrow cells with monoclonal antibody. The percentage of positive cells was calculated. Data are expressed as the means Ϯ SEM of eight mice.
a Significantly different from the vehicle treated mice: P Ͻ 0.05.
at 0.01 g/day, completely restored the decreased BMD to the same level as that of sham-operated mice.
To confirm the recovery of cancellous bone mass by the genistein treatment in OVX mice, bone morphometric analysis was performed using CT in the trabecular bone of the distal femoral metaphysis. The distinct plate-like structure of the bone could be easily seen in the sham-operated mice, and the connecting rods were well maintained (Fig. 5A, left) . In OVX mice, however, the plate-like structure was markedly destroyed, and many of the connecting rods were missing (Fig. 5A, middle) . Treatment with genistein significantly prevented trabecular bone loss in OVX mice, and the threedimensional trabecular bone architecture was reconstructed, becoming similar to that of the sham-operated mice (Fig. 5A,  right) . In OVX mice, the BV density (BV/TV) and the Tb.Th were significantly reduced, whereas the Tb.Sp increased, compared with that of sham-operated mice (Fig. 5B) . The increase in Tb.Sp indicates that the osteoclastic bone resorption was stimulated, resulting in enhanced intertrabecular space. Treatment with genistein completely prevented this decrease in BV/TV and Tb.Th and restored the increase in Tb.Sp.
To define the mechanism of action of genistein, histological sections of distal femoral metaphysis were prepared, and they were stained for TRAP (Fig. 6A) . The number of TRAPpositive multinucleated osteoclasts was significantly increased in trabecular bone obtained from OVX mice, and the treatment with genistein restored it to the sham level (Fig.  6B) . Bone volume (BA/TA) of trabecular bone was markedly suppressed by OVX, and the treatment with genistein significantly recovered it (Fig. 6) . These effects of genistein on bone turnover were similar to those of estrogen. These results indicate that genistein prevents bone loss by suppressing the increased bone resorption caused by estrogen deficiency.
Discussion
The present study clearly demonstrates that genistein, a typical soybean isoflavone, prevents bone loss caused by estrogen deficiency, without substantial effects on the uterus. We previously reported that OVX selectively stimulates Blymphopoiesis, which leads to an accumulation of pre-B cells in mouse bone marrow and that the treatment with estrogen restored the increased B-lymphopoiesis in OVX mice (12) . Like estrogen, genistein prevented the elevation of B-lymphopoiesis in the bone marrow of OVX mice. We also reported that increased B-lymphopoiesis, caused by IL-7, induces bone loss in mice with intact ovarian function, suggesting a close relationship between B-lymphopoiesis and bone resorption (13) . Previous studies have indicated that cell-to-cell interaction between lymphocytes and bone marrow stromal cells can trigger production of bone-resorbing cytokines, such as IL-1 and IL-6, by stromal cells (17, 22, 23) . Increased production of bone-resorbing cytokines may be involved in the mechanism of bone loss caused by estrogen deficiency (16 -18) . Like estrogen, genistein administration recovered both increased B-lymphopoiesis and decreased BV in OVX mice, to the respective sham levels. Therefore, it is likely that the changes in B cell differentiation, caused by genistein in bone marrow, are involved in bone metabolism regulated by this compound.
Genistein completely prevented bone loss caused by es -FIG. 4 . Radiograms of the femora collected from sham-operated mice, OVX mice, and OVX mice treated with genistein or E 2 . Mice were sham-operated or OVX, and some OVX mice were treated with 0.7 mg/day genistein or 0.01 g/day E 2 immediately after surgery. Femora were collected 4 weeks after the operation and were used for xray analysis. Note that marked bone loss occurred in the distal metaphysis of the femoral cancellous bone in OVX mice, and this bone loss was prevented by treatment with genistein or E 2 . trogen deficiency, in CT and histological analyses (Figs. 5 and 6), but BMD was recovered only partially by genistein in OVX mice (Table 3 ). The discrepancy can be explained, because BMD was measured for both cortical and trabecular bone, whereas CT analysis was performed only for the trabecular bone. Therefore, it is possible to speculate that the effect of genistein in cortical bone is relatively less than that in trabecular bone. Genistein has a structural similarity to E 2 ( Fig. 1) but binds weakly to estrogen receptors prepared from rat uterine cytosol with 1/100th affinity, compared with E 2 (7) . Recently, a novel estrogen receptor, termed estrogen receptor-␤ (ER␤), has been cloned from rat prostate and human testis complementary DNA libraries (24, 25) , and the classical estrogen receptor is now called estrogen receptor-␣ (ER␣). Kuiper et al. (26) compared the binding affinity of various estrogenic compounds for ER␣ and ER␤. Genistein possessed a higher affinity for ER␤ than that for ER␣ (26) . Tong et al. (27) also reported genistein's higher affinity for ER␤ using the computed molecular field analysis for structure-activity relationship. Recently, Smithson et al. (28) have suggested that the effect of E 2 on B-lymphopoiesis in bone marrow is mediated by an ER␤-dependent mechanism, because no significant increase in B-lymphopoiesis was found in ER␣ knockout mice. In addition, we have reported that osteoblasts express both ER␣ and ER␤ (29) . Taken together, it is possible to speculate that genistein acts on bone and bone marrow by a mechanism involving ER␤. Further studies are needed to define the mechanism of action of genistein in bone and bone marrow.
It is known that genistein acts as a tyrosine kinase inhibitor (11) . Recent studies indicated that signaling, mediated by Src tyrosine kinase, plays an important role in osteoclast function (30) . Therefore, we cannot rule out the possibility that genistein directly inhibits osteoclastic bone resorption and therefore protects against bone loss caused by estrogen deficiency. To clarify this point, we examined the effect of genistein on osteoclast formation in a co-culture of mouse bone marrow cells and primary osteoblasts, and on an organ culture of fetal mouse calvaria for bone-resorbing assay. Genistein, at 0.4 -10 m, suppressed neither osteoclast formation induced by 2 ng/ml of IL-1 (mean Ϯ sem in N.Oc/ well; control, 0; IL-1, 96.0 Ϯ 6.4; IL-1 ϩ 10 m genistein, 95.6 Ϯ 6.2) nor bone-resorbing activity in mouse calvarial cultures [mean Ϯ sem in released Ca into medium (mg/dl); control, 0.84 Ϯ 0.12; IL-1, 7.7 Ϯ 0.1; IL-1 ϩ 10 m genistein, 7.6 Ϯ 0.1]. Therefore, it is unlikely that genistein acts as a tyrosine kinase inhibitor in bone to prevent increased bone resorption caused by estrogen deficiency. Further studies are necessary to define the mechanism of action of genistein in bone.
It has been shown that the intake of extremely large amounts of isoflavone causes impaired reproductive function in a variety of animal species, because of its estrogenic property (31) (32) (33) . In this study, sc administration of 0.7 mg/ day genistein for 4 weeks did not affect uterine weight, either in OVX or normal mice (Table 1) . Santell et al. (7) reported that the administration of large amounts of dietary genistein (0.375 and 0.75 mg/g diet) increased uterine weight in mature OVX rats but not in immature intact rats. Administration of dietary genistein, however, did not affect the uterotrophic effect of concurrently administered E 2 in OVX rats (7) . Bioavailability of genistein may be influenced by gender, age, or animal species; and the response to genistein may vary with the levels of ERs (ER␣ and ER␤) in each target tissue. Epidemiological studies have suggested that the much lower incidence of diseases caused by estrogen deficiency, such as osteoporosis and heart diseases, in Asian women is attributed to their high intake of isoflavone-rich soyfoods (3) (4) (5) . Indeed, the concentrations of isoflavone in serum and urine in Japanese are higher than those in subjects following Western diets (3, 34, 35) . The daily intake of isoflavones in Asians is estimated at 25-200 mg (36, 37) , and this may account for high levels (10 -100 nm) of active isoflavones in their serum (34) . The serum level of genistein is 100-to 1,000-fold higher than that of endogenous estrogen in premenopausal women (38) . Therefore, genistein may be effective in improving the various symptoms of estrogen deficiency, though it shows only about 1/100th the affinity of E 2 for its receptors.
In this study, we found evidence, for the first time, that genistein significantly reduces bone loss caused by estrogen deficiency, by a mechanism similar to that of estrogen. Arjmandi et al. (6) reported that the administration of soybean protein(s), instead of casein, in the diet prevented bone loss in OVX rats. They speculated that the effects of soybean proteins on bone are attributable to isoflavonoids present in soybeans. Furthermore, Draper et al. (39) demonstrated that phytoestrogen, coumesterol, and zearalanol significantly prevented bone loss in OVX rats. These findings clearly indicate the protective effects of phytoestrogen on bone in a state of estrogen deficiency. In this study, 0.7 mg/day genistein prevented bone loss caused by estrogen deficiency in mice. Further nutritional studies are needed to determine to what extent isoflavone is effective for improving bone metabolism in humans.
In conclusion, an appropriate dosage of genistein restored the increased B-lymphopoiesis and bone loss caused by estrogen deficiency, without exhibiting a substantial effect on the uterus, in OVX mice. Recent studies have shown that synthetic estrogen-related compounds, such as raloxifene, selectively act on bone and on the cardiovascular system without exhibiting estrogenic action in the uterus (2, 40, 41) . In OVX mice, raloxifene exhibited estrogenic actions in bone and bone marrow, preventing bone loss and regulating B-lymphopoiesis, without exhibiting estrogenic action in the uterus (42) . Furthermore, it has been reported that soybean isoflavones improve cardiovascular risk factors without affecting the reproductive system in rhesus monkeys (43) . Therefore, it is likely to speculate that the tissue-selective effects of genistein are similar to that of raloxifene. Intake of soybean products may be useful in preventing bone loss caused by estrogen deficiency.
